October 2018 Research Report

Resverlogix
The Making of a mini-Humira?

Market Cap: US$440 million
Stock Price (10/2/18): C$3.05
Target Price: C$30

Note: Unless otherwise indicated, all dollar amounts are in USD.

About the Company

Resverlogix (RVX CN) is a Calgary, Canada based biotech company whose novel first in class epigenetic small molecule is focused on the needs of high-risk patients suffering from a combination of cardiovascular disease and diabetes mellitus.

Resverlogix is currently in the last stages of a Phase 3 trial with its drug called apabetalone. Its drug has the potential to significantly reduce the incidence of Major Adverse Cardiac Events (MACE) in such high-risk patients. Top line results are expected in the first few months of 2019. Resverlogix also believes that apabetalone can address other indications such as chronic kidney disease, and potentially dementia and Fabry Disease.

Our Thesis

Resverlogix’s molecule is showing signs of having positive impact on several important indications with the potential of becoming the next mini-Humira. Based on excellent Phase 2 data on efficacy and safety, we believe that Phase 3 test results has a very high probability to confirm that RVX-208 remains safe and will meet its endpoint objective of reducing MACE events by at least 25% over standard of care medicines, along with other beneficiary impacts on chronic kidney disease, and potentially dementia. We believe that Resverlogix will most likely be bought out next year after its Phase 3 test results are fully analyzed, or, at the very least, will end up attracting a strategic partner for bringing to market its lead molecule.

Introduction

We are often bemused that when a medical breakthrough is announced, so many of them seem to impact a small number of people. Too many new drugs these days are targeting rare diseases or niche patient groups, with prices often being too high. Can a drug helping so few people really be worth THAT much, we wonder?

In contrast, Resverlogix is a company that addresses cardiovascular disease in a large high-risk patient group — people who have had a recent major adverse cardiac event (MACE), and who have diabetes — with a novel first-in-class small molecule. On top of that, their molecule (RVX-208) shows very promising data on addressing chronic kidney disease, an ailment for which there is no cure today. These are big addressable markets. Even more surprising, Resverlogix has no strategic partner right now.
To get an idea of what a successful result with a new therapeutic for cardiovascular disease could mean, we point to the recent results of the Phase 3 trial run by Amarin (AMRN US). Amarin’s Vascepa medication showed a 25% relative risk reduction in MACE in its trials. That company’s share price went from $3 to $20 within days. After a string of failed Phase 3 trials from other potential drugs, the medical profession badly needs to address a yawning gap in treating cardiovascular disease. Amarin proves that the stock market fully recognizes that.

What can support a belief that Resverlogix will not only be safe, but effective? First, there is mechanistic data analysis from earlier Phase 2 trials, showing very convincing data on early efficacy of cardiovascular disease relative risk reduction after only 26 weeks of treatment. Second, there have been seven successful data and safety monitoring board reviews with no change in protocol.

We see Resverlogix’s small molecule having the potential to follow in the footsteps of Humira, the world’s best-selling drug in 2017. While apabetalone will start off with a single indication, we believe it is highly likely that more indications will be approved over the next few years; exactly like Humira.

The 18-year long road for a company that started off with an interesting concept, and now is on the verge of becoming potentially the world’s next important drug in the cardiovascular field, has been a long and hard one for Resverlogix. The road ahead is longer still, but far more lucrative.

**RVX 208 - Apabetalone**

The genesis of this drug was to meet the objective of boosting apolipoprotein A-I (ApoA-1), the major protein component of HDL-P, so that this would result in coronary plaque regression (like roto rooter for the plaque in your arteries). It is this primary endpoint that Resverlogix was targeting, that first caught our attention several years ago.

The molecule just missed its primary endpoint of plaque regression when the results came out in the 2013 ASSURE Phase 2b trial. However, upon further analysis from its entire Phase 2 program of three clinical trials — ASSERT, SUSTAIN and ASSURE — consistent and statistically significantly relative risk reduction of MACE events were observed. MACE is described as a composite endpoint of nonfatal stroke, nonfatal myocardial infarction (a heart attack that did not kill), and cardiovascular death. This is the most important endpoint in cardiovascular disease risk.

These early Phase 2 trial results with its positive reports relating to MACE effects, as well improved kidney function data, led to a five-year effort for RVX to take the molecule through the current Phase 3 trial in efforts to convincingly prove the MACE reduction and kidney improvements observed in its Phase 2 program.

Before we explain the science, let’s first understand the prize: the addressable market.

**Addressable Market: High Risk Vascular Disease**

Based on the results from its Phase 2 trials, Resverlogix decided to focus their Phase 3 trial on diabetes patients (HbA1c>6.5% or history of diabetic medication) who have had a recent MACE event (7 to 90 days before screening) and low HDL-c (<39 mg/dL). Across the eight top markets (US, Canada, Japan and top five EU countries), there are almost 2 million patients who have such conditions.

Resverlogix seeks to improve the high residual risk that remains in these patients even with standard of care medicines such as statins, beta blockers, aspirin, ace inhibitors and Plavix. These are big markets. 65% of all deaths in people with diabetes are from cardiovascular diseases. 12% of all Americans have diagnosed or undiagnosed diabetes, while another 34% have prediabetes.

Resverlogix has prepared pre-specified secondary endpoints in BETonMACE for chronic kidney disease. The data to be produced from the Phase 3 trial will allow RVX to launch a Phase 2 trial for end stage renal disease (kidney failure) using eGFR to measure renal function.
RVX has another pre-specified endpoint of cognition, using the Montreal Cognitive Assessment tool (MoCA), in all patients in the BETonMACE trial age 70 and older. This is targeting vascular cognitive impairment, or dementia. Success here would be yet another inflection point for the molecule, as currently there are no therapeutic approaches in these areas that have clearly improved cognition.

From an addressable targeted high-risk therapeutic market of over 12 million, including cardiovascular disease, chronic kidney disease, end stage renal disease (kidney failure) and dementia, it is clear that Apabetalone is addressing critical large markets with high unmet need.

A potential price of $5,000 per year and guidance from leading US payers for rapid reimbursement, gives one a sense of the immense commercial potential of this drug. Even if only 1 million patients start taking Apabetalone, that will generate $5 billion a year in sales.

Below is a schematic that captures this opportunity.

![Schematic](source: RVX Commercial Analysis)

We have omitted off label use from the above table. From Phase 2 data, RVX-208 showed efficacy in a more general cardiovascular disease population. This suggests that the true addressable market for RVX-208 is far bigger than the more focused (although more desperate) patient population discussed here. This will provide significant option value for a potential buyer of Resverlogix. For now, we assign no value to this optionality.

**The Science**

To better understand the science, start with cardiovascular disease. Medical science has to a large degree focused a large part of its efforts in reducing LDL cholesterol levels down to as low as possible, primarily through the use of statins and now PCSK9 inhibitors. However, this only appears to reduce the risk of cardiovascular disease by about 30%. Other approaches being tried out have mostly failed to reduce MACE during their Phase 3 trials, such as the CETP drug class.

Cardiovascular disease, chronic kidney disease and diabetes are diseases that are regulated by multiple pathways of risk. What is needed is a medicine that can impact multiple pathways at the same time (an epigenetic drug). Apabetalone is the only epigenetic molecule undergoing Phase 3 trials for cardiovascular disease right now (other epigenetic trials are in cancer). This suggests a lead of seven years for Resverlogix over potential competitive drugs.

The medical paradigm today uses a single molecular target for a single downstream effect. Epigenetic drugs through a single molecular target, concurrently modulate multiple biological processes contributing to a disease state.
Apabetalone, a single molecule for high-risk cardiovascular disease, has been shown to simultaneously target and improve the following processes: vascular inflammation, reverse cholesterol pathway, vascular calcification, metabolism, coagulation pathway, and complement pathway. Improvements in key risk markers such as a) an increase in ApoA-1, the key building block of new functional HDL, b) reduction of alkaline phosphatase, a reported key risk factor for vascular calcification, and c) reduction of vascular inflammation biomarkers including hsCRP and NLR, illustrate the multifactorial approach that this new molecule has illustrated to date.

Human DNA can be considered our hardware. Epigenetics can be considered the software. DNA contains the code that tells our cells what to do. This coded message, whether correct or faulty, is the same in every cell, and does not change with time. Epigenetic changes to the DNA allow the message in the genes to be turned up or down, like a dimmer switch.

Apabetalone is based on targeting a group of BET (bromodomain and extra terminal) proteins. Each of these proteins contain two small regions called “bromodomains”, which play a role in regulating disease causing genes. Compounds that regulate the interaction of these domains may have favorable effects on reducing the level of proteins that play a role in disease.

BET inhibition results in the simultaneous modulation of multiple biological pathways via a single molecular target. RVX-208 preferentially binds to the second bromodomain of BET family members (BRD2, BRD3 and BRD4) with a 20-fold or higher selectivity for the second bromodomain versus the first bromodomain.
Resverlogix is looking at other potential markers regulated by BET inhibition. These ongoing efforts have positioned RVX as a world leader in its novel mechanistic target of select BET inhibition and epigenetic regulation. Interest in BET inhibition has grown substantially over recent years as an exciting new area of drug research. Leading global pharmaceutical companies such as Pfizer and others have dedicated research programs in the area. Resverlogix’s foresight in investing in ongoing research into the area, including performing multiple proteome analysis of serum in patients from its Phase 2 program has provided new emerging pathways and proteins targets that are known driver of risk in cardiovascular and diabetic patients. The institutional knowledge gained by Resverlogix over the years, coupled with no known competitors in the BET space for vascular disease and long patent runways are considered strong reasons for potential buyers to pay even more for Resverlogix than what we forecast here.

The Ongoing Phase 3 Trial

Resverlogix launched its Phase 3 trial (BETonMACE) in October 2015, “Effect of RVX-208 on Time to Major Adverse Cardiovascular Events in High Risk Type 2 Diabetes Mellitus Subjects with Coronary Artery Disease”. Top line results are expected in the first few months of 2019.
The trial is now fully enrolled with about 2,400 patients in 13 countries who are high risk cardiovascular patients with type 2 diabetes mellitus and low HDL. An estimated 12% to 15% of these patients also have chronic kidney disease. This is a double blind, randomized, parallel group, placebo controlled clinical trial to determine whether treatment of apabetalone combined with high dose Crestor or Lipitor and standard of care medicines increase the time to MACE, compared to treatment with Crestor or Lipitor alone.
The primary endpoint is the time to first occurrence of MACE. The trial will continue until at least 250 MACE events have occurred. The trials will be considered a success if the endpoint improves on MACE incidence by 25%. Earlier Phase 2 trials showed far higher efficacy at over 40% relative risk reduction.

The company announced that it had received confirmation from the FDA that if the Phase 3 trial is successful, it is likely to support the filing and approval of a New Drug Application. This is similar to the feedback received from European authorities. This is a critical development as it takes RVX-208 one step closer to acceptance, once Phase 3 is a success.

Secondary endpoints include the hospitalization for cardiovascular disease events (unstable angina and revascularization procedures), changes in HDL and ApoA-I, changes in diabetes mellitus variables (glucose and glycated hemoglobin), changes in ALP, changes in kidney function as well as additional safety and tolerability of apabetalone.

As noted above in our section on Addressable Market, after Phase 3 data has been analyzed, Resverlogix will conduct further Phase 2 tests on patients with end stage renal disease, as well as dementia.

In addition, after Phase 3 trial results are analyzed, Resverlogix plans to then conduct a proof of concept Phase 2a trial for Fabry disease, a rare and serious disease that results from the accumulation of a type of fat called GL-3 in blood vessels, the kidneys, the heart, the nerves and other organs.
Data from Previous Phase 2 Trials

There were three clinical trials with a combined 1,001 subjects participating. 722 received treatment with RVX-208 while 279 received a placebo. Patients treated with RVX-208 had a less cumulative MACE rate of 5.9% versus 10.4% in the placebo treated group. In subgroups, the benefit of RVX-208 appeared more striking in patients with diabetes (5.4% vs 12.7%; p =0.02) and with baseline HDL-c <39 mg/dL (5.5 v 12.8%; p =0.01) or with baseline hsCRP levels > 2 mg/L (5.4% vs 14.2%; p =0.02). The relative risk reductions ranged from 44% to 62%. Such MACE data results are truly conclusive. The company reported that:

The actions of RVX-208 lowered atherogenesis by downregulating (8 of 11) pro-atherogenic genes but in contrast, upregulated (5 of 7) anti-atherogenic genes that control monocyte recruitment, migration and activation, macrophage function, inflammatory signaling and plaque stability.

Regarding toxicity: in one Phase 2 clinical trial, some patients had elevated serum enzymes (markers for liver injury); however other clinical tests indicated that there was no impairment in liver function and patients were asymptomatic for liver injury. Resverlogix has gone through seven data safety monitoring board reviews so far without any noted concerns for an ALT issue. Resverlogix has been instructed to continue the current BETonMACE trial with no changes to its protocol.

From the annual report, this is what they say worked in their trials:

Results demonstrated that apabetalone downregulates pathways that contribute to cardiovascular risk or MACE such as atherosclerosis, thrombosis and inflammation. Specifically, apabetalone downregulated the complement, fibrin clotting, acute phase response, cholesterol and fatty acid synthesis pathways, illustrating repression of most of the pathway components. Overactivation of the complement pathway and acute phase response participate in plaque development and destabilization. Fibrin clotting is fundamental in the formation of thrombi and emboli. Downregulation of these pathways by apabetalone may avoid catastrophic vascular events leading to vessel occlusion and death. Results for several components of the complement and coagulation pathways were verified by real-time PCR, a more sensitive and robust method of measuring mRNA expression, as well as using enzyme-linked immunosorbent assay (“ELISAs”) to measure protein levels. Results were also recapitulated in human hepatocarcinoma cell lines and with BET inhibitors with different chemical scaffolds. In addition, in patients’ plasma from the ASSERT, SUSTAIN and ASSURE clinical trials, apabetalone reduced levels of specific complement, coagulation and acute phase response proteins.
In summary, the data from Phase 2 trials is very clear: the molecule is safe and the trials successfully reduced MACE by large enough magnitudes to qualify for eventual FDA approval.
Management

Resverlogix was founded in 2001 by Donald McCaffrey and Dr. Norman Wong, both of whom are still at the company. McCaffrey is the CEO. Dr. Norman Wong is the author of more than 300 articles and abstracts and sits on over 40 international panels.

The best way to judge a biotech company is to check for peer acceptance of its trials. Who are the principal investigators? The very best scientists get to cherry pick projects they believe will have the best future. Professor Kaushik Ray was the senior principal investigator for the TOGETHER study looking at cardio metabolic risk in the vascular health checks of 250,000 in London. In addition, he is involved in eight ongoing trials in lipids and diabetes, as well as for ORION 1 assessing PCSK9 inhibition through RNA interference. Dr Ginsberg did the same for the landmark ACCORD LIPID trial. And the list goes on for Resverlogix’s steering committee.

Financials

RVX has net debt of US$20 million and a burn rate of US$2.5 million a month. As a result, we expect RVX to need to raise more capital in the next few months.

Once again, its financing will depend on the results of Phase 3 test data.

Why is the valuation on RVX so low?

The market has an institutional memory for every stock. The record of Resverlogix has been detrimental to that memory. First, the company did not meet its stated endpoint goal of achieving plaque regression back in 2013. That was a huge shock to the market from which it took a long time to recover. If that was not bad enough, as a biotech company, RVX has had to raise capital non-stop. The market naturally does not take kindly to be continuously diluted. As recently as May 2018, the share price reached a low of $1.10, far lower than levels seen for many years. It was a stock that had serially disappointed the market, and the market “forgot” about its very existence.

The credibility of the molecule is an issue for biotech analysts. Here is a drug that not only performs far better than existing therapies, in addition, it upends accepted medical wisdom. Most existing drugs are geared towards addressing one malfunctioning protein in the body. To have a proposed drug that will address several malfunctioning proteins through one small molecule, is difficult for many scientists to conceptually accept. This despite the fact that the data from Phase 2 testing is unequivocal and the drug has successfully gone through seven data and safety review boards. All this takes time for markets to absorb.

Another important reason for the market’s current reluctance to revalue RVX is that the recent history of major Phase 3 trials of other promising drugs from other companies have failed. For example, Torectrapib, Dalcetrapib, Niacin trails were all stopped. All these efforts were focused on single protein targets. The market now has a show me attitude to all such tests. But the reaction to Amarin’s Phase 3 test results show that the market will immediately revalue companies if the Phase 3 results are favorable.

Then there is the lack of analyst coverage, little trading volumes in the shares, and a Canadian stock market that is dominated by banks and commodity companies, not biotech. Therefore, what Makalu sees is a grossly undervalued special situations stock.

Is apabetalone the next mini-Humira?

Humira was initially approved in 2003 only for Rheumatoid Arthritis. With further clinical testing, it was later approved for additional indications, including psoriatic arthritis, Crohn’s Disease and plaque psoriasis, among others. Sales for Humira went from $1 billion in 2005 to over $18 billion in 2017. Humira was the world’s best-selling drug in 2017. Today, 1.4 million Americans have Rheumatoid Arthritis, a statistic comparable to the initial indication for RVX-208.
What is most interesting is that Abbott itself never expected such success. Their 2003 annual report forecast peak sales of $1 billion from rheumatoid arthritis, and another $1 billion from additional indications. Yet, by 2004, Humira was already being developed for six additional indications. If you were to calculate the discounted present value (5% discount rates) of the actual sales of Humira as calculated in 2002, then between 2003 and 2017, it adds up to $60 billion. To make a 20% return on sales, it would have justified a nearly $4 billion price to buy Humira from Abbott in 2003. Of course we know that profits grow much faster since margins on selling such drugs exceed 80%. Such calculations are admittedly rough and are meant more to provide a ballpark value to what a blockbuster drug can command.

All this is what we envision apabetalone to become. After cardiovascular disease, the next indication is chronic kidney disease and then dementia. Further down the line is Fabry disease and pulmonary arterial hypertension. While we can only estimate initial sales from RVX-208, we believe the potential to add more indicators make apabetalone the next mini-Humira.

**What is the right price?**

We believe Resverlogix will be bought out soon after its topline data comes out in 2019. Why isn’t a company buying them out right now? The recent history of promising heart disease molecules failing in Phase 3 trials haunts potential buyers. In other words, RVX-208 results need to conclusively meet its MACE relative risk reduction target of 25% and is shown to remain safe. Executives at such potential buyers of Resverlogix would rather pay a lot more with a lot less uncertainty than the other way around.

For the buyer of Resverlogix, a key question is whether RVX-208 will be accepted by insurance companies, or will it go the way of PCSK9 inhibitors (simply too expensive to be acceptable to most insurance companies). Below is a table from 5 leading US Payers stating their ICER threshold of $140,000 to $200,000 to prevent one MACE event.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Lives Covered</th>
<th>MACE Reduction: Unmet need in Recent ACS and T2DM patients</th>
<th>MACE Reduction: Unmet need in CKD patients</th>
<th>ICER Threshold per annum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payer 1</td>
<td>55 M</td>
<td>Moderate to High</td>
<td>Moderate to High</td>
<td>$ &lt; 100,000</td>
</tr>
<tr>
<td>Payer 2</td>
<td>65 M</td>
<td>Moderate to High</td>
<td>Moderate to High</td>
<td>$ &lt; 200,000</td>
</tr>
<tr>
<td>Payer 3</td>
<td>37 M</td>
<td>Moderate to High</td>
<td>Moderate to High</td>
<td>$ &lt; 100,000</td>
</tr>
<tr>
<td>Payer 4</td>
<td>40 M</td>
<td>Moderate to High</td>
<td>Moderate to High</td>
<td>$ &lt; 150,000</td>
</tr>
<tr>
<td>Payer 5</td>
<td>11 M</td>
<td>Moderate to High</td>
<td>Moderate to High</td>
<td>$ &lt; 150,000</td>
</tr>
</tbody>
</table>

*Source: Resverlogix BIO 2018 Presentation*

Since insurance companies are willing to pay for a MACE averted ($100,000 to $200,000), it then becomes a simple calculation to figure out how much a drug can get priced. The key unknown variable is relative risk reduction from apabetalone. The higher the reduction, the higher the price the drug can command. Based on numbers needed to treat (NNT) of about 25 to 60 (for a 40% and 25% RRR), the estimates indicate that $5,000 price in the US should be acceptable.

In short, apabetalone is a very viable drug for a rapid reimbursement from health insurance companies, which in turn drives compelling commercial opportunity for the molecule.

Recent novel CVD therapeutic approach who have successfully completed Phase 3 trials provide a powerful example of this value inflection point. Amarin declared efficacy for 25% relative risk
reduction in MACE event with their purified fish oil over an average of 3.9 years treatment. Once this data came out their enterprise value grew from $1 billion US to almost US$6 billion in a matter of days. If we use that metric, Resverlogix can be argued to have a potential similar value of approximately $30 US a share, which would be over ten times from today’s enterprise value. While Amarin is a good comparison, it is not an apple to apple comparison. Amarin has a purified fish oil prescription medicine which can be used by a more general population with elevated triglycerides and or one of more cardiovascular risk factors.

Apabetalone has been planned to pursue high risk patients where the drug has compelling data of efficacy. These patients, having experienced a near death experience (ACS), a come to Jesus moment, have a very high compliance rate for ongoing use of the molecule. This in addition with potential use in chronic kidney disease and Dementia patients are additional markets where continuous and chronic dosing to take this drug are a must. This also makes for a very desirable commercial property from the seller of apabetalone’s point of view. Like Humira, its use in future indications can easily expand with more clinical testing, allowing for even higher pricing of the molecule. Therefore, we see $30 per share as the lower bound of what any drug company will pay for RVX.

We get a Net Present Value of about $4 billion using conservative penetration rates for three indications. Almost 60% comes from the earliest indication (cardiovascular disease in diabetic and low HDL patients), another 30 percentage points from cardiovascular disease and chronic kidney disease patients, and the rest from Dementia. However, as we know, penetration rates can be much higher than our conservative estimates, and the potential for additional indications and off label use, can push estimated Net Present Value significantly higher.

**Risks**

Resverlogix’s future depends on the results of its Phase 3 trial.

If, against all expectations (and particularly Phase 2 data), Phase 3 results do not meet the primary endpoint of MACE relative risk reduction, then the shares would be impacted negatively.

So far there have no toxicity concerns with Apabetalone in its current Phase 3 trial. Seven consecutive drug safety and monitoring review board reports have allowed the trial to continue with no changes in the clinical protocol. Such assessments provide an additional level of comfort that the drug to date is safe. Any unexpected data showing toxicity in Phase 3 may cause the FDA to ask Resverlogix to conduct more trials. This request, if it came, would significantly delay the ability of Resverlogix to apply for Apabetalone approval, and raise questions about the molecule.

Resverlogix will need more capital to continue its clinical trials. A failure of Phase 3 would severely curtail their ability to raise capital. The company expects to list on the NASDAQ, but a failure of this trial may make that a very difficult equity offering.

**Summary**

Resverlogix owns a novel first in class small molecule that is showing signs of having the potential to becoming the next mini-Humira.

Based on convincing Phase 2 data, we expect that Phase 3 results will show that Apabetalone remains safe and will most likely meet its endpoint of relative risk reduction of MACE events by at least 25%, along with other beneficiary impacts on chronic kidney disease patients and elderly patients with some form of cognition issues.

At the very least, we expect Resverlogix to have a strategic partner after successful Phase 3 test results are fully analyzed; most likely Resverlogix will get bought out for over $30.
Resverlogix Data

Founded 2001 / listed 2005
Toronto XTSE
Calgary, Canada

GICS Classifications: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology

Auditor: KPMG LLP

Income Statement: Net Loss of US$58 million
Balance Sheet: Net Debt of US$20 million
Cash flow: Cash burn of US$2.5 million a month
IMPORTANT DISCLAIMERS AND DISCLOSURES

Current Information
Opinions expressed here of Makalu Fund Management, LLC (“Makalu”) are current opinions only as of the date appearing in this material. Any projections, market outlooks or estimates in this presentation are forward-looking statements and are based upon internal analysis and certain assumptions, which reflect the views of Makalu and should not be construed to be indicative of actual events which will occur. As such, the information may change in the future should any of the economic or market conditions Makalu used to base its assumptions change.

General
This publication circulated by Makalu Fund Management, LLC (“Makalu”) is designed to highlight various market and economic information and is not intended to interpret laws or regulations. The information contained in this document is confidential and proprietary and intended only for use by the recipient. The information contained herein is not complete, and does not contain certain material information about hedge funds (each a “Fund” or collectively, the “Funds”), including important disclosures and risk factors associated with an investment in a Fund, and is subject to change without notice. This document is not intended to be, nor should it be construed or used as an offer to sell, or a solicitation of any offer to buy shares or limited partnership interests in a Fund. If any offer is made to invest in a Fund, it shall be pursuant to a definitive Private Placement Memorandum prepared by or on behalf of the Fund which contains detailed information concerning the investment terms and the risks, fees and expenses associated with an investment in the Fund. Neither the Securities and Exchange Commission nor any state securities administrator has approved or disapproved, passed on, or endorsed, the merits of these securities.

Examples of specific discrete investments are included to illustrate the investment process of Makalu and strategies it may use. The Fund’s portfolio typically will contain a much larger number of positions than the examples discussed; accordingly, the examples are not intended to indicate overall performance of the Fund nor read as a recommendation for any specific investment. It should not be assumed that recommendations in the future will be profitable or will equal the performance of the securities in this list.

Performance
As with any investment vehicle, past performance cannot assure any level of future results. Certain performance calculations are prepared internally and have not been audited or verified by a third party. The use of a different methodology for preparing, calculating or presenting performance returns may lead to different results and such differences may be material.

Risks
Investments in hedge funds entail substantial risks and are not intended as a complete investment program. The profitability and return on hedge fund investments are dependent upon numerous factors, which may include the active management of securities, both long and short, across global markets, including, but not limited to, equities, foreign exchange, fixed income, commodities, futures, options, swaps and other derivative instruments. Opportunities for redemption and transferability of interests in hedge funds are generally restricted so investors may not have access to capital when it is needed. There is generally no secondary market for interests in the hedge funds and none is expected to develop.

Hedge funds are designed only for sophisticated investors who are able to bear the economic risk of losing all of their investment. Hedge Funds: (1) often engage in leverage and other speculative investment practices that may increase the risk of investment loss; (2) can be highly illiquid; (3) are not required to provide periodic pricing or valuation information to investors; (4) may involve complex tax structures and delays in distributing important tax information; (5) are not subject to the same regulatory requirements as mutual funds; and (6) often charge high fees.
Use of Indices
Market index information shown herein, including but not limited to the S&P 500 is included to show relative market performance for the periods indicated and not as standards of comparison, since these are unmanaged, broadly based indices which differ in numerous respects from the portfolio composition of the Funds. Market index information was compiled from sources that Makalu believes to be reliable. No representation or guarantee is made hereby with respect to the accuracy or completeness of such data.